Skan Group successfully launches its IPO on SIX. The advisors
On October 27, 2021, Skan Group has announced the pricing of its IPO, consisting of 1,731,494 newly issued shares and 2,768,506 existing shares and an over-allotment option of up to 500,000 shares, at CHF 54 per share, implying a total market capitalisation of CHF 1.214 billion. Skan Group will receive gross proceeds from the issuance of the new shares in an amount of approximately CHF 93.5 million. The shares will be listed and start trading today on SIX Swiss Exchange (SIX: SKAN). Settlement of the IPO is expected to occur on November 1, 2021
The existing shares were mainly offered by the current majority shareholder Dr. Willy Michel, along with sales by certain other existing shareholders of Skan Group. Credit Suisse and Berenberg are acting as joint global coordinators and joint bookrunners, and KPMG as independent financial advisor of Skan Group.
Skan is a global market and technology provider for isolators, cleanroom equipment and decontamination processes for the aseptic production of active biopharmaceutical ingredients. The company operates in markets with the highest regulatory requirements in the healthcare sector – mainly in Europe, North America, Japan, South Korea and Singapore.
The advisors
Lenz & Staehelin advised Skan Group as issuer’s counsel. The team was led by partners Stephan Erni (pictured right) and Patrick Schleiffer (pictured left). The team also included associates Patrick Schärli, Patrick Sattler and Nicole Humbel and junior associate Nina Beeler (all capital markets / corporate), as well as partner Pascal Hinny and associate Lukas Aebi (both tax).
Advestra acted as legal counsel to Credit Suisse and Berenberg. The team included partner Alexander von Jeinsen (pictured left), associates Annina Hammer, Anna Capaul and Valérie Bayard as well as partner Thomas Reutter (all capital markets and corporate/ m&a) and partner Markus Mühlemann (tax).
